

AMENDMENTS TO THE CLAIMS:

- 1-13. (Cancelled)
14. (Withdrawn-currently amended) A method for immunotherapy comprising the step of administering to a subject in need of such immunotherapy the pharmaceutical composition according to claim ~~13~~ 25.
15. (Cancelled)
16. (Withdrawn) The method according to claim 14, wherein said immunotherapy is a therapy against acute transplant rejections.
17. (Withdrawn-currently amended) A method for gene therapy comprising the step of administering to a subject in need of such gene therapy ~~[[a]] the pharmaceutical composition comprising the polynucleotide of claim 9 or the expression vector of claim 10 according to claim 25.~~
- 18-20. (Cancelled)
21. (Currently amended) A bivalent diabody comprising a non-covalent dimer of single chain F_V antibodies each consisting essentially of a V_H domain and a V_L domain specific to human CD3, wherein the V_H domain and the V_L domain are covalently linked either without a linker or via a peptide linker; the bivalent diabody is characterized by the following features:
- (a) it is devoid of constant antibody domains;
 - (b) it specifically binds to human TCR/CD3 complex bivalently; and
 - ~~(b)~~ (c) it is capable of suppressing an immune reaction.
22. (Previously presented) The bivalent diabody according to claim 21, wherein the V_H domain and the V_L domain are covalently linked via a peptide linker SAKTTP (SEQ ID

NO:1).

23. (Previously presented) The bivalent diabody according to claim 21, wherein the V_H and the V_L domains correspond to the variable domains of an antibody produced by the hybridoma of ATCC deposit number CRL 8001.
24. (Currently amended) The antibody according to claim 23, wherein a cysteine at position H100A according to the Kabat numbering system has been exchanged for ~~another amine acid~~ a serine.
25. (Previously presented) A pharmaceutical composition comprising the bivalent diabody of claim 21 and a suitable pharmaceutical carrier.
26. (New) The pharmaceutical composition of claim 25, wherein the suitable pharmaceutical carrier is selected from the group consisting of an emulsion, a wetting agent and a sterile solution.
27. (New) The pharmaceutical composition of claim 26, wherein the composition is a sterile solution.